| Literature DB >> 28673958 |
Christoph Kronenberg1, Tim Doran2, Maria Goddard2, Tony Kendrick3, Simon Gilbody2, Ceri R Dare4, Lauren Aylott4, Rowena Jacobs5.
Abstract
BACKGROUND: Serious mental illness (SMI) - which comprises long-term conditions such as schizophrenia, bipolar disorder, and other psychoses - has enormous costs for patients and society. In many countries, people with SMI are treated solely in primary care, and have particular needs for physical care. AIM: The objective of this study was to systematically review the literature to create a list of quality indicators relevant to patients with SMI that could be captured using routine data, and which could be used to monitor or incentivise better-quality primary care. DESIGN ANDEntities:
Keywords: pay-for-performance schemes; primary care; quality indicators; serious mental illness; systematic review
Mesh:
Year: 2017 PMID: 28673958 PMCID: PMC5519123 DOI: 10.3399/bjgp17X691721
Source DB: PubMed Journal: Br J Gen Pract ISSN: 0960-1643 Impact factor: 5.386
Figure 1.
Quality of care indicators identified for people with serious mental illness
| 1 | Coordinated care — identify key worker (social worker or CPN) | Routine data | |||
| 2 | Staff continuity — good communication between staff and infrequent staff changes | Routine data | |||
| 3 | Continuity: CONNECT is a patient questionnaire with 72 items, each rated on a five-point scale, with 13 scales and one single-item indicator: General coordination — ‘Overall, is your mental health treatment well coordinated?’ Primary care scales — ‘How often is psychiatrist in contact with your primary care doctor?’ (Never, Rarely, Sometimes, Often, Always) | Primary data | |||
| 4 | Total number of follow-up contacts during treatment episode after initial evaluation | Routine data | |||
| 5 | Patients with SMI who smoke who are offered tobacco counselling/help to stop smoking | Routine data | |||
| 6 | Alcohol misuse screening | Routine data | |||
| 7 | Screening for illicit drug use, type, quantity, and frequency | Routine data | |||
| 8 | Referral to substance misuse disorder specialty care, if appropriate | Routine data | |||
| 9 | HIV screening with co-occurring substance misuse for SMI service users | Routine data | |||
| 10 | Practice can produce register of all SMI patients | Routine data | |||
| 11 | Service user registration with a primary health organisation | Routine data | |||
| 12 | Markers of care recorded: contact with secondary health services, written care plans, 6-month mental health review, identified care coordinator, evidence of physical examination | Routine data | |||
| 13 | Patients who do not attend the practice for their annual review who are identified and followed up by the practice team | Routine data | |||
| 14 | System contact: number of patients in contact with the treatment system | Routine data | |||
| 15 | Surveillance to prevent relapse | Routine data | |||
| 16 | Crisis management and out-of-hours services | Routine data | |||
| 17 | Access to services and range of services | Routine data | |||
| 18 | Family care — record of families living with person with schizophrenia | Primary data | |||
| 19 | Duration of untreated psychosis: number of recently diagnosed patients | Routine data | |||
| 20 | Waiting time between registration and start of treatment | Routine data | |||
| 21 | All current medication clearly available at all consultations — known drug dosages, frequencies, history of side effects, review date | Primary data | |||
| 22 | Monitor patients suffering extra pyramidal effects, check compliance | Routine data | |||
| 23 | Assess weight gain, use of concomitant medication | Routine data | |||
| 24 | Use of lithium: plasma lithium levels monitored regularly | Routine data | |||
| 25 | Percentages of bipolar service users prescribed antidepressants and anxiolytics | Routine data | |||
| 26 | Proportion of patients who are receiving depot antipsychotics who have appropriate laboratory screening tests | Routine data | |||
| 27 | Patients have their antipsychotic medication reviewed regularly, considering symptoms and side effects: appropriate referral to specialist | Routine data | |||
| 28 | Polypharmacy: reduce number of patients using more than four psychotropic drugs at the same time | Routine data | |||
| 29 | Monitoring patients with neurological, sexual, sleeping, and sedation side effects | Routine data | |||
| 30 | Percentage of patients given annual mental health review by GP | Routine data | |||
| 31 | Comprehensive mental status examination and history conducted in patients with a new treatment episode | Routine data | |||
| 32 | Referral for specialist mental health assessment | Routine data | |||
| 33 | Comprehensive assessment of comorbid psychiatric conditions and response to treatment | Routine data | |||
| 34 | Reassess severity of symptoms | Routine data | |||
| 35 | Examined for duration of untreated psychosis | Primary data | |||
| 36 | Delayed diagnosis | Primary data | |||
| 37 | Informal carer contacts | Primary data | |||
| 38 | Information on employment status | Primary data | |||
| 39 | Diabetes monitoring for people with diabetes and schizophrenia | Routine data | |||
| 40 | Diabetes and cholesterol monitoring for people with schizophrenia and diabetes | Routine data | |||
| 41 | Diabetes screening for people who are using antipsychotic medications | Routine data | |||
| 42 | Blood pressure screening for patients with diabetes | Routine data | |||
| 43 | Weight management/BMI monitoring | Routine data | |||
| 44 | Proportion with increased BMI/abdominal waistline | Routine data | |||
| 45 | Patients with diabetes who received education about diabetes, nutrition, cooking, physical activity, or exercise | Routine data | |||
| 46 | Counselling on physical activity and/or nutrition for those with documented elevated BMI | Routine data | |||
| 47 | Retinal exam for patients with SMI who have diabetes | Routine data | |||
| 48 | Foot exam for patients with SMI who have diabetes | Routine data | |||
| 49 | Hypertension counselling: patients with hypertension who received education services related to hypertension, nutrition, cooking, physical activity, or exercise | Routine data | |||
| 50 | Hypertension: recording and monitoring patients with hypertension and high blood cholesterol (LDL) | Routine data | |||
| 51 | Breast cancer screening for women | Routine data | |||
| 52 | Colorectal cancer screening | Routine data | |||
| 53 | Proportion of patients who have an increased blood pressure | Routine data | |||
| 54 | Proportion of patients who have an increased blood glucose level | Routine data | |||
| 55 | Proportion of patients who have low levels of glycosylated haemoglobin | Routine data | |||
| 56 | Proportion of patients who have increased level of blood lipids | Routine data | |||
| 57 | Comprehensive physical health assessment with appropriate advice | Routine data | |||
| 58 | Patients with diabetes who received psychoeducation related to weight (BMI), diabetes (blood glucose levels) | Routine data | |||
| 59 | Medical attention for nephropathy | Routine data | |||
AHRQ = Agency for Healthcare Research and Quality. BMI = body mass index. CPN = community psychiatric nurse. LDL = low-density lipoprotein. QOF = Quality and Outcomes Framework. SMI = serious mental illness.
Quality of evidence of studies identifying quality of care indicators for people with serious mental illness
| Parameswaran, Spaeth-Rublee, Pincus | 656 measures of quality of mental health care identified in earlier work are rated in importance, validity, and feasibility, using a modified Delphi process | 3 |
| NICE | NICE treatment guidelines for bipolar disorder | 4 |
| NICE | NICE treatment guidelines for schizophrenia | 4 |
| AHRQ | AHRQ provides a database of quality indicators that was used during the grey literature search | 4 |
| Lester, Tritter, Sorohan | Focus groups with patients, GPs, and nurses were conducted to explore how to improve care in cases of acute mental health crises | 3 |
| Sweeney, Rose, Clement, | Structured interviews were conducted with 167 individuals suffering from psychoses to establish a concept of service user-defined continuity of care | 3 |
| Ware, Dickey, Tugenberg, McHorney | This study reports on the field testing of an interview-based measure of continuity of care | 3 |
| Cerimele, Chan, Chwastiak, | Narrative description of 740 primary care patients with bipolar who participated in an MHIP. Quality of care outcomes were derived from patient disease registry | 3 |
| Pincus, Spaeth-Rublee, Watkins | Discussion on the barriers to measuring quality of care in the mental health arena, combined with a short list of potential quality measures | 3 |
| Holden | This study audited 16 GPs on their care for 266 patients with schizophrenia and observed that the audit led to improved recording of a range of quality indicators | 3 |
| Swartz, MacGregor | The authors of this paper argue that in South Africa the role of mental health nurses has been altered to focus on violence, substance misuse, and HIV/AIDS, and should be refocused on psychiatry care in the primary care setting | 3 |
| Ruud | The author summarises the literature on quality of care in mental health services in Norway in 2008–2009 | 3 |
| Highet, McNair, Thompson, | Interviews with 49 patients with bipolar to describe experience in primary care in Australia. Eight themes for improvement of the primary care experience are outlined | 3 |
| Lader | Expert review of the standards of care in schizophrenia to reduce side effects while achieving best treatment outcomes | 3 |
| Haro, Salvador-Carulla | Observational study following 11 000 patients who were on or changing antipsychotic medication to determine the best course of treatment with respect to symptoms, quality of life, social functioning, and other outcomes | 2 |
| Caughey, Kalish Ellett, Wong | Development, expert review, and assessment of the evidence base for, and validity of, medication-related indicators of potentially preventable hospitalisations | 3 |
| Busch, Lehman, Goldman, Frank | Observational study examining trends in four measures of quality over time in the US | 2 |
| Young, Sullivan, Burnam, Brook | Uncontrolled study looking at differences in quality of care as variations from national guidelines | 3 |
| Nayrouz, Ploumaki, Farooq, | Evaluation of an integrated care approach between primary care and community care, focused on patients with SMI | 3 |
| McCullagh, Morley, Dodwell | This observational study looks at urban versus rural differences in quality of care for psychoses, as well as the difference in quality of care conditional on contacts with secondary care | 3 |
| Rodgers, Black, Stobbart, Foster | Audit of quality of care in 822 Scottish patients with schizophrenia | 3 |
| Osborn, Nazareth, Wright, King | Randomised trial to evaluate the impact of a nurse-led treatment to improve screening for CVD in the SMI population | 1 |
| Yeomans, Dale, Beedle | Evaluation of a computer-based physical health screening template versus NICE guidelines for the SMI population | 3 |
| Mitchell, Delaffon, Lord | A systematic review and meta-analysis of screening practices with respect to metabolic risks for patients with psychosis | 1 |
| Roberts, Roalfe, Wilson, Lester | A retrospective view of case notes in 22 GP practices to determine whether patients with schizophrenia receive equitable physical health care | 3 |
| Mainz, Hansen, Palshof, Bartels | Description of the Danish National Indicator Project, which intends to document and advance quality of care | 3 |
| Druss, Zhao, Cummings, | The study compared diabetes performance measures in US Medicaid enrolees with and without mental comorbidity | 2 |
Quality of evidence51 is categorised as: 1. High — Cochrane or systematic review, randomised control trial. 2. Moderate — non-randomised control study or unsystematic review. 3. Low — expert opinion, uncontrolled studies. 4. Not applicable — measure was extracted from grey literature, for example, (non-)government organisations’ documents or databases. AHRQ = Agency for Healthcare Research and Quality. CVD = cardiovascular disease. MHIP = mental health integration programme. NICE = National Institute for Health and Care Excellence. SMI = Serious mental illness.
| 1 serious mental illness*.tw. (2037) | 39 Ambulatory Care/ (36401) |
| 2 serious mental disorder*.tw. (260) | 40 or/32–39 (268786) |
| 3 serious psychiatric illness*.tw. (61) | |
| 4 serious psychiatric ill-health*.tw. (0) | 41 Quality Indicators, Health Care/ (10737) |
| 5 serious mental ill-health*.tw. (0) | 42 (quality adj2 indicat*).tw. (6747) |
| 6 serious psychiatric disorder*.tw. (130) | 43 (quality adj2 measure*).tw. (12491) |
| 7 severe mental illness*.tw. (2679) | 44 (quality adj2 criteria).tw. (3829) |
| 8 severe mental disorder*.tw. (720) | 45 (performance adj2 indicat*).tw. (4837) |
| 9 severe mental ill-health*.tw. (2) | 46 (performance adj2 measure*).tw. (14194) |
| 10 severe psychiatric illness*.tw. (128) | 47 (performance adj2 criteria).tw. (1367) |
| 11 severe psychiatric disorder*.tw. (379) | 48 (incentive* adj3 scheme*).tw. (207) |
| 12 severe psychiatric ill-health*.tw. (0) | 49 (incentive* adj3 assess*).tw. (96) |
| 13 major mental disorder*.tw. (288) | 50 (incentive* adj3 measure*).tw. (152) |
| 14 major mental illness*.tw. (350) | 51 (incentive* adj3 outcome*).tw. (96) |
| 15 major psychiatric illness*.tw. (151) | 52 “Standard of Care”/ (1049) |
| 16 major psychiatric ill-health*.tw. (0) | 53 (standard* adj2 care).tw. (25676) |
| 17 major psychiatric disorder*.tw. (730) | 54 (standard* adj2 healthcare).tw. (400) |
| 18 major mental ill-health*.tw. (0) | 55 “Quality of Health Care”/ (58460) |
| 19 schizophrenia/ or schizophrenia, catatonic/ or schizophrenia, disorganized/ or schizophrenia, paranoid/ or shared paranoid disorder/ (86432) | 56 (quality adj2 (healthcare or care)).tw. (39007) |
| 20 (Schizophrenia* or schizophrenic or dementia praecox).tw. (90771) | 57 patient outcome assessment/ (934) |
| 21 Schizotypal Personality Disorder/ (2217) | 58 (patient adj2 outcome assessment*).tw. (70) |
| 22 (disorder* adj2 schizotypal).tw. (702) | 59 (patient adj2 outcome measure*).tw. (2492) |
| 23 (disorder* adj1 delusional).tw. (703) | 60 proms.tw. (263) |
| 24 Psychotic Disorders/ (32708) | 61 patient satisfaction/ or patient preference/ (63756) |
| 25 ((psychotic adj2 disorder*) or (schizoaffective adj2 disorder*) or psychoses or psychosis or schizophreniform).tw. (38127) | 62 (patient* adj2 satisfaction).tw. (26024) |
| 26 bipolar disorder/ or cyclothymic disorder/ (32171) | 63 (patient* adj2 experience*).tw. (59692) |
| 27 (Bipolar adj2 (disorder* or depression or depressive or psychosis or psychoses)).tw. (22038) | 64 (patient* adj2 preference*).tw. (8103) |
| 28 (Manic state* or mania).tw. (8053) | 65 quality.tw. (594390) |
| 29 (Manic adj2 (disorder* or depression or depressive or psychosis or psychoses)).tw. (4445) | 66 or/41–65 (782974) |
| 30 (cyclothymic disorder* or cyclothymic personalities or cyclothymic personality).tw. (95) | |
| 31 or/1–30 (179930) | 67 31 and 40 and 66 (551) |
| 32 exp Primary Health Care/ (82203) | 68 limit 67 to yr=”1990 -Current” (537) |
| 33 general practitioners/ or physicians, family/ or physicians, primary care/(18403) | |
| 34 general practice/ or family practice/ (64455) | |
| 35 (family adj2 pract*).tw. (11764) | |
| 36 (primary adj2 care).tw. (89376) | |
| 37 (general adj2 pract*).tw. (69034) | |
| 38 (family adj2 physician*).tw. (12969) |
| Title | 1 | Identify the report as a systematic review, meta-analysis, or both. | 1 |
| ABSTRACT | |||
| Structured summary | 2 | Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number. | 1 |
| Rationale | 3 | Describe the rationale for the review in the context of what is already known. | 1 |
| Objectives | 4 | Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS). | N/A |
| Protocol and registration | 5 | Indicate if a review protocol exists, if and where it can be accessed (for example, web address), and, if available, provide registration information including registration number. | N/A |
| Eligibility criteria | 6 | Specify study characteristics (for example, PICOS, length of follow-up) and report characteristics (for example, years considered, language, publication status) used as criteria for eligibility, giving rationale. | 2 |
| Information sources | 7 | Describe all information sources (for example, databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched. | 2 |
| Search | 8 | Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated. | 11 |
| Study selection | 9 | State the process for selecting studies (that is, screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis). | 4 |
| Data collection process | 10 | Describe method of data extraction from reports (for example, piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators. | 4 |
| Data items | 11 | List and define all variables for which data were sought (for example, PICOS, funding sources) and any assumptions and simplifications made. | 5 |
| Risk of bias in individual studies | 12 | Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis. | N/A |
| Summary measures | 13 | State the principal summary measures (for example, risk ratio, difference in means). | N/A |
| Synthesis of results | 14 | Describe the methods of handling data and combining results of studies, if done, including measures of consistency (for example, I2) for each meta-analysis. | N/A |
| Risk of bias across studies | 15 | Specify any assessment of risk of bias that may affect the cumulative evidence (for example, publication bias, selective reporting within studies). | N/A |
| Additional analyses | 16 | Describe methods of additional analyses (for example, sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified. | N/A |
| Study selection | 17 | Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram. | 6 |
| Study characteristics | 18 | For each study, present characteristics for which data were extracted (for example, study size, PICOS, follow-up period) and provide the citations. | 5 |
| Risk of bias within studies | 19 | Present data on risk of bias of each study and, if available, any outcome level assessment (see item 12). | N/A |
| Results of individual studies | 20 | For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group; and (b) effect estimates and confidence intervals, ideally with a forest plot. | N/A |
| Synthesis of results | 21 | Present results of each meta-analysis done, including confidence intervals and measures of consistency. | N/A |
| Risk of bias across studies | 22 | Present results of any assessment of risk of bias across studies (see Item 15). | N/A |
| Additional analysis | 23 | Give results of additional analyses, if done (for example, sensitivity or subgroup analyses, meta-regression [see Item 16]). | N/A |
| Summary of evidence | 24 | Summarise the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (for example, healthcare providers, users, and policymakers). | 7 |
| Limitations | 25 | Discuss limitations at study and outcome level (for example, risk of bias), and at review level (for example, incomplete retrieval of identified research, reporting bias). | 7 |
| Conclusions | 26 | Provide a general interpretation of the results in the context of other evidence, and implications for future research. | 7 |
| Funding | 27 | Describe sources of funding for the systematic review and other support (for example, supply of data); role of funders for the systematic review. | 8 |